stockrow
Saturday 7 November 2026
Export CCCC’s income statement to Excel — free account
C4 Therapeutics, Inc.
CCCC Healthcare Biotechnology
C4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024.
- Revenue
- −24.6%
- EPS
- +63.6%
- Free cash flow
- +17.9%
Quarter to September 2026, against a year earlier
3.12
0.17
+5.76%
Follow CCCC
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 3 | 4 |
+8 more TTM periods Free account |
| (47.62%) | (48.14%) | (48.35%) | (44.44%) | ||
| (30.50%) | (30.92%) | (32.02%) | (29.63%) | ||
ROIC |
(279.99%) | 0.00% | 0.00% | (894.58%) | |
Return on Tangible Assets |
(51.50%) | (46.35%) | (46.63%) | (45.68%) | |
Average Days of Receivables |
15.89 | 13.90 | 30.19 | 24.38 | |
Free Cash Flow per Share |
(0.59) | (0.65) | (0.76) | (1.20) | |
Free Cash Flow |
(79.63) | (85.39) | (96.02) | (99.30) | |
Capital Expenditures |
— | (0.52) | (0.67) | (0.60) | |
| Other line items | |||||
Cash ROIC |
(18.37%) | (17.05%) | (20.43%) | (19.66%) | |
Accounts Receivable Turnover |
8.12 | 20.07 | 6.39 | 13.06 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
306.29% | 285.53% | 291.94% | 289.98% | |
Selling, General and Administrative Expense of Revenue |
109.56% | 102.81% | 103.83% | 100.69% | |
Share Based Compensation of Revenue |
39.33% | 40.83% | 46.65% | 53.13% | |
Interest Coverage |
— | 8.63 | 8.75 | 6.70 | |
Operating CF/Net income |
0.87 | 0.84 | 0.92 | 0.94 | |
Depreciation/Fixed assets |
0.00 | (0.26) | (0.25) | (0.17) | |
Capex/Depreciation |
— | 0.49 | 0.59 | 0.77 | |
Revenue per Share |
0.24 | 0.27 | 0.28 | 0.43 | |
Operating CF per Share |
(0.59) | (0.65) | (0.76) | (1.19) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.01 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026